Editorial: After the storm: Neurofilament levels as a surrogate endpoint for neuroaxonal damage

Neurology

Volumn 76, Issue 14, 2011, Pages 1200-1201

  Giovannoni, Gavin ^a   Nath, Avindra ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; INTERFERON; ISOPROTEIN; MONOCLONAL ANTIBODY; NATALIZUMAB; NEUROFILAMENT PROTEIN; PROTEIN 14 3 3; TAU PROTEIN; DIAGNOSTIC AGENT;

ALZHEIMER DISEASE; BLOOD; CEREBROSPINAL FLUID; CHEMOLUMINESCENCE; CLINICAL ASSESSMENT; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DEPHOSPHORYLATION; DIFFUSION TENSOR IMAGING; DISABILITY; DISEASE ACTIVITY; DISEASE SEVERITY; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SPACE; HIV ASSOCIATED COGNITIVE IMPAIRMENT; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NERVE CELL LESION; NEUROAXONAL DAMAGE; NEUROFILAMENT; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RISK ASSESSMENT; SPINAL CORD INJURY; STROKE; VISUAL ACUITY; NERVE CELL; NERVE FIBER; NOTE; PATHOLOGY;

AXONS; BIOLOGICAL MARKERS; HUMANS; MULTIPLE SCLEROSIS; NEUROFILAMENT PROTEINS; NEURONS;

EID: 79954754563     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182143345     Document Type: Editorial

References (16)

1. Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:402-404. (Pubitemid 28159853)
2. Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003;61:1720-1725. (Pubitemid 38020818)
3. Salzer J, Svenningsson A, Sundstrom P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010;16:287-292.
4. Petzold A, Eikelenboom MJ, Keir G, et al. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J Neurol Neurosurg Psychiatry 2005;76:206-211. (Pubitemid 40143709)
5. Semra YK, Seidi OA, Sharief MK. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol 2002;122:132-139. (Pubitemid 34075499)
6. Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, Giovannoni G. Quantification of neurodegeneration by measurement of brain-specific proteins. J Neuroimmunol 2003;138:45-48. (Pubitemid 36566417)
7. Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res 2003; 987:25-31. (Pubitemid 37267883)
8. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285. (Pubitemid 28065253)
9. Petzold A, Eikelenboom MI, Keir G, et al. The new global multiple sclerosis severity score (MSSS) correlates with axonal but not glial biomarkers. Mult Scler 2006;12:325-328. (Pubitemid 43827188)
10. Kuhle J, Leppert D, Petzold A, et al. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology 2011;76:1206-1213.
11. Petzold A, Rejdak K, Plant GT. Axonal degeneration and inflammation in acute optic neuritis. J Neurol Neurosurg Psychiatry 2004;75:1178-1180. (Pubitemid 39005781)
12. Petzold A, Brassat D, Mas P, et al. Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis. Mult Scler 2004;10:281-283. (Pubitemid 38807455)
13. Petzold A, Altintas A, Andreoni L, et al. Neurofilament ELISA validation. J Immunol Methods 2010;352:23-31.
14. Kuhle J, Regeniter A, Leppert D, et al. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. J Neuroimmunol 2010;220:114-119.
15. Lu CH, Kalmar B, Malaspina A, Greensmith L, Petzold A. A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament "hook" effect. J Neurosci Methods 2011;195:143-150.
16. Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol Epub 2010 Oct 28.